Lupus Nephritis Market to Extend at a CAGR of 8.4% by 2032 | DelveInsight

The Lupus Nephritis market is anticipated to show positive growth owing to factors such as increasing prevalence, strong pipeline activity, and the presence of multiple Large-Cap Pharma players.

LAS VEGAS, June 6, 2022 /PRNewswire/ -- DelveInsight's Lupus Nephritis Market Insights report proffers a detailed comprehension of the lupus nephritis market size by treatment, epidemiology, emerging therapies, lupus nephritis market share of the individual therapies, current and forecasted lupus nephritis market size from 2019 to 2032 segmented into 7MM (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan).

Some of the salient features from the Lupus Nephritis Market report: 

• As per DelveInsight's analysis, the total lupus nephritis market in the 7MM is expected to grow at a CAGR of 8.4% during the study period 2019-2032.
• Key companies currently working in the market include names such as Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research & Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc., Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca, Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others.
• The lupus nephritis pipeline therapies include GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Zanubrutinib, Ravulizumab, Anifrolumab, Itolizumab, and others that are expected to launch in the upcoming years.
• As per our estimates, the total lupus nephritis market size in the United States accounted for USD 975.1 million in 2021, which is likely to rise during the study period.

For further information on market impact by therapies, download the lupus nephritis market sample @lupus nephritis therapeutic market landscape

Overview

Lupus Nephritis is a common and potentially devastating exhibitionof systemic lupus erythematosus. It is a leading cause of morbidity and mortality in patients with SLE. LN leads to inflammation of small blood vessels which play an essential role in filtering waste materials in the kidney. It also involves the inflammation of glomeruli.

Common lupus nephritis signs include hematuria, proteinuria, edema, and sudden weight gain. It is vital that patients with lupus have routine urine analysis with microscopy looking for protein, blood, and cellular casts. Lupus nephritis is primarily caused by the deposition of immune complexes. The size of the complexes determines the deposition location, which leads to differences in classification. There are five types of lupus nephritis. Treatment is based on the type of lupus nephritis, determined by the biopsy. Since symptoms and severity vary from person to person, treatments are individually tailored to meet a person's particular circumstances.

Lupus Nephritis Epidemiology Segmentation

According to DelveInsight's analysis, the total diagnosed cases of lupus nephritis in the 7MM were approximately  209k cases in 2021 that are anticipated to increase by 2032.

The lupus nephritis market report offers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into-

• Prevalent population of lupus nephritis
• Total diagnosed population of lupus nephritis
• Gender-specific prevalent population of lupus nephritis
• Class-Specific cases of lupus nephritis 
• Clinical manifestations of lupus nephritis

Learn more about the lupus nephritis population trends for the 7MM by downloading @lupus nephritis epidemiological forecast report

The lupus nephritis treatment landscape currently has some approved therapies, while the principal goal of the present treatment regimen is to normalize renal function or, at least, prevent the progressive loss of renal function. However, therapy differs depending on the pathologic lesion.

The lupus nephritis treatment strategies briefly emphasize the maximal preservation of renal function and patient protection from long-term consequences, mainly end-stage renal disease (ESRD) requiring dialysis or renal transplantation. In general, the mainstays for addressing lupus nephritis are mainly dominated by glucocorticosteroids (prednisone or methylprednisolone), immunosuppressants (cyclophosphamide, azathioprine, mycophenolate mofetil (MMF), others (monoclonal antibodies, such as rituximab), and adjunctive therapies (such as hydroxychloroquine, angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blockers, etc.).

In January 2021, Aurinia Pharmaceuticals, a spin-out from Vifor Pharma, announced that FDA approved Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active lupus nephritis. The approval of voclosporin is based on data taken from two positive pivotal trials – the AURORA Phase III study and the AURA-LV Phase II study.

In December 2020, GlaxoSmithKline announced that FDA approved Benlysta (belimumab) in intravenous and subcutaneous formulations for the treatment of adult patients with active lupus nephritis, receiving standard therapy.

Talking about the emerging lupus nephritis treatment landscape, several companies, including Roche, Novartis, AstraZeneca, and Boehringer Ingelheim, are eyeing the existing untapped market of lupus nephritis and trying their best to grab a significant market share in the 7MM. Some of the emerging therapies had already demonstrated positive late-stage results among the lupus nephritis-affected individuals and include therapies such as-

·  GAZYVA – being developed by Roche, a third-generation, first humanized and glycoengineered CD20-directed cytolytic antibody, which is in the Phase III stage of clinical development.

·  Saphnelo (Anifrolumab) – being produced by AstraZeneca, an investigational, fully human monoclonal antibody

·  Novartis's Iscalimab – a new, fully human, monoclonal antibody, etc.

Discover which therapy is expected to grab a substantial lupus nephritis market share by downloading the report snapshot @lupus nephritis market landscape

Key Lupus Nephritis Pipeline Therapies and Companies

• GAZYVA: Roche
• Saphnelo (Anifrolumab): AstraZeneca
• Iscalimab: Novartis 
• Cosentyx: Novartis 
• Zanubrutinib: BeiGene
• Ravulizumab: Alexion Pharmaceuticals
• Anifrolumab: AstraZeneca
• Itolizumab: Equillium

To know about more pipeline therapies, check @lupus nephritis pipeline analysis, clinical trials, and emerging therapies 

Lupus Nephritis Market Drivers and Barriers

Factors responsible for the anticipated growth in the lupus nephritis market include the increasing prevalence of this disease assisted by organizational support and a promising pipeline constituting late-stage products that are expecting their approval. Other additional factors are extensive research and development, awareness, and a surge in the number of clinical studies contributing to the lupus nephritis market growth.

On the contrary, several aspects such as a high cost of treatment, the need for novel therapeutics as well as a need for a targeted treatment regimen can all serve as potential lupus nephritis market drawbacks.

Know which lupus nephritis therapy is expected to score the touchdown first @lupus nephritis market landscape and forecast

Scope of the lupus nephritis market report

• Study period: 2019–2032
• Coverage: 7MM (The United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)
• Key lupus nephritis companies: Aurinia Pharmaceuticals, Roche, AstraZeneca, Boehringer Ingelheim, Novartis, Novartis Pharmaceuticals, Hoffmann-La Roche, Janssen Research and Development, BeiGene, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Alexion Pharmaceuticals, Omeros Corporation, Corestem, Inc.,  Bristol-Myers Squibb, Boehringer Ingelheim, Apellis Pharmaceuticals, AstraZeneca,  Kezar Life Sciences, Equillium, Eledon Pharmaceuticals, Resolve Therapeutics, and others
• Key  lupus nephritis pipeline therapies: GAZYVA, Saphnelo (Anifrolumab), Iscalimab, Cosentyx, Zanubrutinib, Ravulizumab, Anifrolumab, Itolizumab, and others
• Therapeutic assessment:  lupus nephritis current marketed and emerging therapies
• Market dynamics:  lupus nephritis market drivers and barriers 
• Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Market Access and Reimbursement

Discover more about the future market share of  lupus nephritis treatment therapies @lupus nephritis market forecast

Table of Contents 

For further information on Market Impact by Therapies @lupus nephritis market analysis

Get in touch with our Business executive @lupus nephritis market landscape analysis 

Related Reports

Graft-versus-host disease (GvHD) Market 

DelveInsight's "Graft-versus-host disease (GvHD) Market Insights Report" offers comprehensive details of pathophysiology and various diagnostic approaches, treatment algorithms. The report also offers profiling of GvHD pipeline therapeutics, ongoing Graft versus host disease clinical trials, key cross competition, and key pharmaceuticals like Medac, MaaT Pharma, ElsaLys Biotech (Mediolanum Farmaceutici Spa), Syndax Pharmaceutical, Kadmon Corporation, AstraZeneca, Biogen, Amgen, Pfizer, Bristol-Myers Squibb, CTI BioPharma, Novartis, GlaxoSmithKline, and several others.

IgA Nephropathy Epidemiology

DelveInsight's "IgA Nephropathy (IgAN) – Epidemiology Forecast to 2030" report delivers an in-depth understanding of the disease, historical and forecasted IgA Nephropathy (IgAN) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Epstein–Barr Virus-associated Post-transplant Lymphoproliferative Disease Market 

DelveInsight's "Epstein–Barr Virus-associated Post-transplant Lymphoproliferative Disease – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the Epstein–Barr virus-associated post-transplant lymphoproliferative disease, treatment algorithms, profiling of pipeline therapeutics, ongoing clinical trials, key cross competition, and key pharmaceuticals involved.

Chronic Renal/Kidney Transplant Rejection Market 

DelveInsight's "Chronic Renal/Kidney Transplant Rejection – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the chronic renal/kidney transplant rejection, ongoing clinical trials, key cross competition, and key pharmaceuticals involved.

IgA Nephropathy Pipeline

DelveInsight's "IgA Nephropathy – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles and key companies involved are Novartis AG, Reata Pharmaceuticals, Chinook Therapeutics, Aravive, Omeros Corporation, Vera Therapeutics, Apellis Pharmaceuticals, Inc,N and others

Lichen Planus Market

DelveInsight's "Lichen Planus – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the Lichen Planus, historical and forecasted epidemiology, current treatment practices, emerging drugs, and unmet medical needs.

Guillain–Barre Syndrome Market

DelveInsight's "Guillain–Barre Syndrome (GBS) – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the Guillain–Barre Syndrome (GBS), historical and forecasted epidemiology, current treatment practices, emerging drugs, and unmet medical needs.

Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market

DelveInsight's "Chronic Inflammatory Demyelinating Polyradiculoneuropathy – Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of the Chronic Inflammatory Demyelinating Polyradiculoneuropathy, historical and forecasted epidemiology as well as current treatment practices, emerging drugs,  treatment practice/algorithm, unmet medical needs.

Autoimmune Hepatitis Market

DelveInsight's "Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast – 2030" report delivers an in-depth understanding of Autoimmune Hepatitis, historical and forecasted epidemiology as well as current treatment practices, emerging drugs, and unmet medical needs.

Psoriatic Arthritis Market

DelveInsight's "Psoriatic Arthritis (PsA) – Market Insights, Epidemiology, and Market Forecast – 2030" report deliver an in-depth understanding of the historical and forecasted epidemiology profiling of pipeline therapeutics, and key pharmaceuticals involved like AbbVie, Amgen/Pfizer, Bristol-Myers Squibb, Janssen Biotech, Amgen, Eli Lilly and Company, Pfizer, UCB, Bristol-Myers Squibb, Sun Pharma Global FZE, and many others.

Browse Through Our Blog Posts

• Graft vs Host Disease (GvHD): Treatment approaches and trends
• Autologous cell therapy market: A new paradigm for kidney diseases
• Is antibody-mediated rejection a roadblock to organ transplantation?

About DelveInsight

DelveInsight is a leading business consultant and market research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us -  LinkedIn|Facebook|Twitter

Contact Us
Shruti Thakur 
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com  

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg